- Home
- SSKN vs CLRB Comparison
SSKN vs CLRB Comparison
Compare SSKN & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSKN
- CLRB
- Stock Information
- Founded
- SSKN 1989
- CLRB 2002
- Country
- SSKN United States
- CLRB United States
- Employees
- SSKN N/A
- CLRB N/A
- Industry
- SSKN Medical/Dental Instruments
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- SSKN Health Care
- CLRB Health Care
- Exchange
- SSKN Nasdaq
- CLRB Nasdaq
- Market Cap
- SSKN 12.3M
- CLRB 10.7M
- IPO Year
- SSKN 2005
- CLRB N/A
- Fundamental
- Price
- SSKN $2.91
- CLRB $0.24
- Analyst Decision
- SSKN
- CLRB Buy
- Analyst Count
- SSKN 0
- CLRB 2
- Target Price
- SSKN N/A
- CLRB $28.00
- AVG Volume (30 Days)
- SSKN 10.3K
- CLRB 3.3M
- Earning Date
- SSKN 11-13-2024
- CLRB 11-18-2024
- Dividend Yield
- SSKN N/A
- CLRB N/A
- EPS Growth
- SSKN N/A
- CLRB N/A
- EPS
- SSKN N/A
- CLRB N/A
- Revenue
- SSKN $32,674,999.00
- CLRB N/A
- Revenue This Year
- SSKN $0.94
- CLRB N/A
- Revenue Next Year
- SSKN $11.30
- CLRB N/A
- P/E Ratio
- SSKN N/A
- CLRB N/A
- Revenue Growth
- SSKN N/A
- CLRB N/A
- 52 Week Low
- SSKN $2.51
- CLRB $0.22
- 52 Week High
- SSKN $6.00
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- SSKN 43.72
- CLRB 18.75
- Support Level
- SSKN $2.94
- CLRB $0.27
- Resistance Level
- SSKN $3.08
- CLRB $0.33
- Average True Range (ATR)
- SSKN 0.15
- CLRB 0.03
- MACD
- SSKN -0.00
- CLRB 0.05
- Stochastic Oscillator
- SSKN 12.82
- CLRB 10.38
About SSKN Strata Skin Sciences Inc.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.